12 active not recruiting. 12 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Active not recruiting 12 |
| Phase 1 | 4 | Active not recruiting 4 |
Follow Turcot syndrome: new trials by email Literature Review of Turcot syndrome trials Research Report on Turcot syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors GSK4418959, PD-1 inhibitor - Neoplasms, Colorectal, Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 14 | 2024-12-13 | 2026-02-02 |
| Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer Camrelizumab - Colon Cancer, Mismatch Repair Deficiency | Phase 2 | Active not recruiting | Peking Union Medical College Hospital | 18 | 2024-01-01 | 2026-07-21 |
| Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer Cadonilimab - Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR) | Phase 1 / Phase 2 | Active not recruiting | Sun Yat-sen University | 28 | 2023-02-07 | 2026-06-24 |
| T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors Pembrolizumab, E7777 - Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Active not recruiting | Alexander B Olawaiye, MD | 25 | 2022-09-30 | 2026-05-29 |
| Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin Atezolizumab, IMM-101 - Colorectal Cancer | Phase 2 | Active not recruiting | AIO-Studien-gGmbH | 80 | 2021-12-10 | 2025-06-15 |
| A Beta-only IL-2 ImmunoTherapY Study MDNA11, Pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | Medicenna Therapeutics, Inc. | 160 | 2021-08-27 | 2026-10-30 |
| A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation Pembrolizumab - Metastatic Castration Resistant Prostate Cancer | Phase 2 | Active not recruiting | VA Office of Research and Development | 40 | 2020-02-20 | 2026-09-21 |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers Tumor Infiltrating Lymphocytes (TIL), Fludarabine + Cyclophosphamide combination - Gastric Cancer, Colorectal Cancer | Phase 2 | Active not recruiting | Udai Kammula | 20 | 2019-12-03 | 2026-06-01 |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab - Non-Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 2 | Active not recruiting | ImmunityBio, Inc. | 40 | 2018-12-11 | 2026-01-14 |
| Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor Nivolumab, Relatlimab - Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 38 | 2018-11-16 | 2026-10-08 |
| Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) RP1, nivolumab - Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H) | Phase 2 | Active not recruiting | Replimune, Inc. | 340 | 2017-09-20 | 2026-02-13 |
| Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer Danvatirsen, Durvalumab - Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 39 | 2017-03-02 | 2025-05-06 |
Colorectal Neoplasms (7) · Carcinoma, Merkel Cell (3) · Carcinoma, Non-Small-Cell Lung (3) · Melanoma (3) · Microsatellite Instability (3) · Stomach Neoplasms (3) · Carcinoma, Ovarian Epithelial (2) · Carcinoma, Renal Cell (2) · Colonic Neoplasms (2) · Endometrial Neoplasms (2) · Pancreatic Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Uterine Cervical Neoplasms (2) · Carcinoma, Basal Cell (1)
Neoplasms by Site (11) · Neoplasms (10) · Colonic Diseases (8) · Digestive System Diseases (8) · Digestive System Neoplasms (8) · Gastrointestinal Diseases (8) · Gastrointestinal Neoplasms (8) · Intestinal Diseases (8) · Intestinal Neoplasms (8) · Rectal Diseases (7) · Genital Diseases (5) · Neoplasms by Histologic Type (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Carcinoma (4)
pembrolizumab (4) · Nivolumab (3) · atezolizumab (2) · durvalumab (2) · ALT-803 (1) · Cyclophosphamide (1) · Disulfides (1) · Docetaxel (1) · E7777 fusion protein (1) · IMM-101 (1) · Immune Checkpoint Inhibitors (1) · Immunoglobulin G (1) · Interleukin-2 (1) · avelumab (1) · camrelizumab (1)
AIO-Studien-gGmbH (1) · Alexander B Olawaiye, MD (1) · GlaxoSmithKline (1) · ImmunityBio, Inc. (1) · M.D. Anderson Cancer Center (1) · Medicenna Therapeutics, Inc. (1) · Peking Union Medical College Hospital (1) · Replimune, Inc. (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Sun Yat-sen University (1) · Udai Kammula (1) · VA Office of Research and Development (1)
United States (9) · Spain (3) · Australia (2) · China (2) · Germany (2) · South Korea (2) · Belgium (1) · Canada (1) · France (1) · Ireland (1) · Japan (1) · Netherlands (1) · Portugal (1) · Switzerland (1) · United Kingdom (1)
Alexander Olawaiye, MD (1) · Arash Yavari, MBBS (1) · David S Hong (1) · Dung Le, MD (1) · Jeannie Hou, MD (1) · Matthew B. Rettig, MD (1) · Nina Merchant (1) · Stefan Kasper-Virchow, MD (1) · Udai S Kammula, MD (1)
PMID 31399043, PMID 38022532, PMID 39886125, PMID 40627813
2016 (1), 2023 (1), P50CA062924 (1)